Related references
Note: Only part of the references are listed.Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
Tomáš Šimůnek et al.
Pharmacological Reports (2014)
Trace elements of normal, benign hypertrophic and cancerous tissues of the Human prostate gland investigated by neutron activation analysis
Sofia Zaichick et al.
APPLIED RADIATION AND ISOTOPES (2012)
Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy
Y. Yu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures
Gerard Lescoat et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2012)
N-myc downstream regulated gene 1 modulates Wnt-ß-catenin signalling and pleiotropically suppresses metastasis
Wen Liu et al.
EMBO MOLECULAR MEDICINE (2012)
Cellular transport and homeostasis of essential and nonessential metals
Ebany J. Martinez-Finley et al.
METALLOMICS (2012)
Mitochondrial Mayhem: The Mitochondrion as a Modulator of Iron Metabolism and Its Role in Disease
Michael Li-Hsuan Huang et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
M. Domenica Cappellini et al.
BLOOD (2011)
MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements
Sebastian Giulianelli et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Role of ferritin alterations in human breast cancer cells
Svitlana I. Shpyleva et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats
V. Ashutosh Rao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer
Lance D. Miller et al.
CANCER RESEARCH (2011)
Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
David B. Lovejoy et al.
CANCER RESEARCH (2011)
Activation of the HIF Prolyl Hydroxylase by the Iron Chaperones PCBP1 and PCBP2
Anjali Nandal et al.
CELL METABOLISM (2011)
Iron chaperones for mitochondrial Fe-S cluster biosynthesis and ferritin iron storage
Poorna Subramanian et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2011)
Human STEAP3 maintains tumor growth under hypoferric condition
Taichi Isobe et al.
EXPERIMENTAL CELL RESEARCH (2011)
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Chrisostomi Gialeli et al.
FEBS JOURNAL (2011)
Iron as a target of chemoprevention for longevity in humans
Shinya Toyokuni
FREE RADICAL RESEARCH (2011)
Zinc is decreased in prostate cancer: an established relationship of prostate cancer!
Leslie C. Costello et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2011)
The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity
Yu Yu et al.
MOLECULAR PHARMACOLOGY (2011)
Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer
Zaklina Kovacevic et al.
MOLECULAR PHARMACOLOGY (2011)
Deferoxamine for Advanced Hepatocellular Carcinoma
Takahiro Yamasaki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Advances in metal-induced oxidative stress and human disease
Klaudia Jomova et al.
TOXICOLOGY (2011)
Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins
Paula Martinez et al.
NATURE REVIEWS CANCER (2011)
Regulation of apoptosis-associated lysosomal membrane permeabilization
Ann-Charlotte Johansson et al.
APOPTOSIS (2010)
Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status
Junqiang Tian et al.
CANCER LETTERS (2010)
Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC # 663249) for Locally Advanced Cervical Cancer
Charles A. Kunos et al.
CLINICAL CANCER RESEARCH (2010)
Differential regulation of iron homeostasis during human macrophage polarized activation
Stefania Recalcati et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
Emanuela Messa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Polarization dictates iron handling by inflammatory and alternatively activated macrophages
Gianfranca Corna et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release
Elena Sierra-Filardi et al.
IMMUNOBIOLOGY (2010)
A phase II trial of TriapineA® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
Anne M. Traynor et al.
INVESTIGATIONAL NEW DRUGS (2010)
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
Patric J. Jansson et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2010)
Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity
Patric J. Jansson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Six-Transmembrane Epithelial Antigen of the Prostate as an Immunotherapeutic Target for Renal Cell and Bladder Cancer
Makoto Azumi et al.
JOURNAL OF UROLOGY (2010)
Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer
Suzana Kukulj et al.
MEDICAL ONCOLOGY (2010)
The missing Zinc: p53 misfolding and cancer
Stewart N. Loh
METALLOMICS (2010)
Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
Zandra K. Pinnix et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Iron: An emerging factor in colorectal carcinogenesis
Anita C. G. Chua et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells
Egarit Noulsri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma
Takao Kamai et al.
BMC CANCER (2009)
Haem and folate transport by proton-coupled folate transporter/haem carrier protein 1 (SLC46A1)
Abas H. Laftah et al.
BRITISH JOURNAL OF NUTRITION (2009)
The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase IIα in Breast Cancer Cells
V. Ashutosh Rao et al.
CANCER RESEARCH (2009)
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
Junko H. Ohyashiki et al.
CANCER SCIENCE (2009)
Role of iron in carcinogenesis: Cancer as a ferrotoxic disease
Shinya Toyokuni
CANCER SCIENCE (2009)
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
Anshul Gupte et al.
CANCER TREATMENT REVIEWS (2009)
COPPER AND ANGIOGENESIS: UNRAVELLING A RELATIONSHIP KEY TO CANCER PROGRESSION
Lydia Finney et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2009)
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study
Ali Taher et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Modulation of Iron-Regulatory Genes in Human Hepatocellular Carcinoma and Its Physiological Consequences
Michelle Guet Khim Tan et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2009)
Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in -thalassemia
Totsapol Jirasomprasert et al.
FREE RADICAL RESEARCH (2009)
The iron chelator Dp44mT does not protect myocytes against doxorubicin
Brian B. Hasinoff et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2009)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
Yu Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Regulatory effects of ferritin on angiogenesis
Lan G. Coffman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Overexpression of cellular iron import proteins is associated with malignant progression of Esophageal adenocarcinoma
Jessica Boult et al.
CLINICAL CANCER RESEARCH (2008)
The Fenton activity of iron(III) in the presence of deferiprone
Lakshmi D. Devanur et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine((R))) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders
Judith E. Karp et al.
LEUKEMIA RESEARCH (2008)
Regulation of iron acquisition and storage: consequences for iron-linked disorders
Ivana De Domenico et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
A cytosolic iron chaperone that delivers iron to ferritin
Haifeng Shi et al.
SCIENCE (2008)
Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens
B. Furusato et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2008)
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
Brigette Ma et al.
INVESTIGATIONAL NEW DRUGS (2008)
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium
M. J. Mackenzie et al.
INVESTIGATIONAL NEW DRUGS (2007)
Deferasirox for transfusion-related iron overload: A clinical review
Wesley T. Lindsey et al.
CLINICAL THERAPEUTICS (2007)
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism
G. Lescoat et al.
CELL PROLIFERATION (2007)
Phase II study of triapinea® in patients with metastatic renal cell carcinoma:: A trial of the national cancer institute of canada clinical trials group (NCIC IND.161)
Jennifer J. Knox et al.
INVESTIGATIONAL NEW DRUGS (2007)
Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C
Junji Kato et al.
JOURNAL OF GASTROENTEROLOGY (2007)
Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents
Danuta S. Kalinowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Direct interorganellar transfer of iron from endosome to mitochondrion
Alex D. Sheftel et al.
BLOOD (2007)
Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo
Pia M. Challita-Eid et al.
CANCER RESEARCH (2007)
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression
Effie Nurtjahja-Tjendraputra et al.
BLOOD (2007)
Future of toxicology-iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy
Danuta S. Kalinowski et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2007)
Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles
Daniel R. Rhodes et al.
NEOPLASIA (2007)
Effects of metal ions, catechins, and their interactions on prostate cancer
Hai-Ning Yu et al.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2007)
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption
Andong Qiu et al.
CELL (2006)
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
Zaklina Kovacevic et al.
CARCINOGENESIS (2006)
Modulation of cell proliferation and polyamine metabolism in rat liver cell cultures by the iron chelator O-trensox
Francois Gaboriau et al.
BIOMETALS (2006)
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity
Des R. Richardson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Megan Whitnall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Expression of iron regulatory genes in a rat model of hepatocellular carcinoma
Petra Holmstrom et al.
LIVER INTERNATIONAL (2006)
Modulation of iron transport proteins in human colorectal carcinogenesis
M. J. Brookes et al.
GUT (2006)
Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells
Juan P. Liuzzi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer
E. Angst et al.
BRITISH JOURNAL OF CANCER (2006)
The role of iron regulatory proteins in mammalian iron homeostasis and disease
Tracey A. Rouault
NATURE CHEMICAL BIOLOGY (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer
Maja Prutki et al.
CANCER LETTERS (2006)
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox
Karine Chantrel-Groussard et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Common presence of non-transferrin-bound iron among patients with type 2 diabetes
DH Lee et al.
DIABETES CARE (2006)
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
MD Cappellini et al.
BLOOD (2006)
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
A Sica et al.
EUROPEAN JOURNAL OF CANCER (2006)
Iron dysregulation and neurodegeneration - The molecular connection
DW Lee et al.
MOLECULAR INTERVENTIONS (2006)
Free radicals, metals and antioxidants in oxidative stress-induced cancer
M Valko et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2006)
A ferrous-Triapine complex mediates formation of reactive oxygen species chat inactivate human ribonucleotide reductase
JM Shao et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis
KA O'Donnell et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma
L Brard et al.
GYNECOLOGIC ONCOLOGY (2006)
CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin
DJ Schaer et al.
BLOOD (2006)
N-picolyl derivatives of Kemp's triamine as potential antitumor agents:: A preliminary investigation
CAS Regino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Iron Imports. II. Iron uptake at the apical membrane in the intestine
B Mackenzie et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2005)
The evolution of iron chelators for the treatment of iron overload disease and cancer
DS Kalinowski et al.
PHARMACOLOGICAL REVIEWS (2005)
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation
J Turner et al.
BLOOD (2005)
Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells
RS Ohgami et al.
NATURE GENETICS (2005)
Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice
H Gunshin et al.
BLOOD (2005)
hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer
Renty B. Franklin et al.
MOLECULAR CANCER (2005)
Identification of an intestinal heme transporter
M Shayeghi et al.
CELL (2005)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Polyamines and apoptosis
N Seiler et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
Ferritins: Dynamic management of biological iron and oxygen chemistry
XF Liu et al.
ACCOUNTS OF CHEMICAL RESEARCH (2005)
Cell permeable iron chelators as potential cancer chemotherapeutic agents
PMB Pahl et al.
CANCER INVESTIGATION (2005)
Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study
F Gaboriau et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Iron: a target for the management of Kaposi's sarcoma?
T Simonart
BMC CANCER (2004)
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
J Yuan et al.
BLOOD (2004)
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
E Nemeth et al.
SCIENCE (2004)
Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression
S Bandyopadhyay et al.
ONCOGENE (2004)
Structure, function, and mechanism of ribonucleotide reductases
M Kolberg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
Synthesis and potent antitumor activities of novel 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives
HS Chong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
Y Yen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Nickel(II), copper(II) and zinc(II) binding properties and cytotoxicity of tripodal, hexadentate tris(ethylenediamine) - analogue chelators
N Ye et al.
DALTON TRANSACTIONS (2004)
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator
R Zhao et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion
S Wadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Iron chelators in cancer chemotherapy
JL Buss et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2004)
Polyamine-iron chelator conjugate
RJ Bergeron et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Labile iron pool: the main determinant of cellular response to oxidative stress
M Kruszewski
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2003)
The effect of potent iron chelators on the regulation of p53:: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1
SX Liang et al.
CARCINOGENESIS (2003)
Targeting mTOR signaling for cancer therapy
S Huang et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice
T Simonart et al.
GYNECOLOGIC ONCOLOGY (2003)
Antiangiogenic therapy through copper chelation
M Sproull et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2003)
The role of iron chelation in cancer therapy
JL Buss et al.
CURRENT MEDICINAL CHEMISTRY (2003)
The metallobiology of Alzheimer's disease
AI Bush
TRENDS IN NEUROSCIENCES (2003)
Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents
EM Becker et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia
M Cazzola et al.
BLOOD (2003)
The role of oxidant injury in the pathophysiology of human thalassemias
SL Schrier et al.
REDOX REPORT (2003)
Trace elements in human physiology and pathology. Copper
H Tapiero et al.
BIOMEDICINE & PHARMACOTHERAPY (2003)
Hexadentate hydroxypyridonate iron chelators based on TREN-Me-3,2-HOPO: Variation of cap size
JD Xu et al.
INORGANIC CHEMISTRY (2002)
Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway
ZM Qian et al.
PHARMACOLOGICAL REVIEWS (2002)
Evaluation of new iron chelators and their therapeutic potential
F Aouad et al.
INORGANICA CHIMICA ACTA (2002)
Synthesis of 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives as potential antitumor agents
HS Chong et al.
JOURNAL OF ORGANIC CHEMISTRY (2002)
The labile iron pool: Characterization, measurement, and participation in cellular processes
O Kakhlon et al.
FREE RADICAL BIOLOGY AND MEDICINE (2002)
Transport of toxic metals by molecular mimicry
N Ballatori
ENVIRONMENTAL HEALTH PERSPECTIVES (2002)
Serum and tissue trace elements in patients with breast cancer in Taiwan
HW Kuo et al.
BIOLOGICAL TRACE ELEMENT RESEARCH (2002)
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia
IR Wanless et al.
BLOOD (2002)
Novel hybrid iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells
DB Lovejoy et al.
BLOOD (2002)
Activation of caspase pathways during iron chelator-mediated apoptosis
BT Greene et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Mechanisms underlying the cytotoxic effects of Tachpyr - a novel metal chelator
AM Samuni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2002)
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients
A Ceci et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Nuclear transcription factor-κB as a target for cancer drug development
A Garg et al.
LEUKEMIA (2002)
Lipid peroxidation and protein modificationin a mouse model of chronic iron overload
MA Sochaski et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Comparative studies on the iron chelators O-TRENSOX and TRENCAMS:: selectivity of the complexation towards other biologically relevant metal ions and Al3+
F Biaso et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2002)
Anti proliferative and apoptotic effects of iron chelators on human cervical carcinoma cells
T Simonart et al.
GYNECOLOGIC ONCOLOGY (2002)
Meat consumption and colorectal cancer risk: Dose-response meta-analysis of epidemiological studies
T Norat et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial
A Maggio et al.
BLOOD CELLS MOLECULES AND DISEASES (2002)
Anti-leukemia activity of 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-one derivatives
J Guillon et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2002)
Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers
MY Moridani et al.
BIOCHEMICAL PHARMACOLOGY (2001)
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator
RD Abeysinghe et al.
CARCINOGENESIS (2001)
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression
J Gao et al.
BLOOD (2001)
A human mitochondrial ferritin encoded by an intronless gene
S Levi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Characterization of a human plasma membrane heme transporter in intestinal and hepatocyte cell lines
MT Worthington et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2001)
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
CH Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
An iron-regulated ferric reductase associated with the absorption of dietary iron
AT McKie et al.
SCIENCE (2001)
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease
AL Fracanzani et al.
HEPATOLOGY (2001)
Genotoxicity of iron chelators in L5178Y mouse lymphoma cells
P Whittaker et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2001)
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)
GJ Kontoghiorghes et al.
TRANSFUSION SCIENCE (2000)
Iron homeostasis: Insights from genetics and animal models
NC Andrews
NATURE REVIEWS GENETICS (2000)
Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors
T Simonart et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Mixed hydroxypyridinonate ligands as iron chelators
SM Cohen et al.
INORGANIC CHEMISTRY (2000)
A novel mammalian iron-regulated protein involved in intracellular iron metabolism
S Abboud et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
RA Finch et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines
N Rakba et al.
CARCINOGENESIS (2000)
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
A Donovan et al.
NATURE (2000)
Modulation of telomerase activity by zinc in human prostatic and renal cancer cells
K Nemoto et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis
C Chapoutot et al.
GUT (2000)
Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors?
RG Schipper et al.
SEMINARS IN CANCER BIOLOGY (2000)
A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation
AT McKie et al.
MOLECULAR CELL (2000)
Share Paper
